LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 29

Search options

  1. Article ; Online: Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.

    Palandri, F / Auteri, G / Abruzzese, E / Caocci, G / Bonifacio, M / Mendicino, F / Latagliata, R / Iurlo, A / Branzanti, F / Garibaldi, B / Trawinska, M M / Cattaneo, D / Krampera, M / Mulas, O / Martino, E A / Cavo, M / Vianelli, N / Impera, S / Efficace, F /
    Heidel, F / Breccia, M / Elli, E M / Palumbo, G A

    Annals of hematology

    2024  Volume 103, Issue 6, Page(s) 1931–1940

    Abstract: Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) ... ...

    Abstract Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9% to 26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.
    MeSH term(s) Humans ; Primary Myelofibrosis/drug therapy ; Nitriles ; Pyrimidines/therapeutic use ; Pyrazoles/therapeutic use ; Male ; Polycythemia Vera/drug therapy ; Female ; Prospective Studies ; Aged ; Middle Aged ; Italy/epidemiology ; Medication Adherence/statistics & numerical data ; Aged, 80 and over ; Adult
    Chemical Substances ruxolitinib (82S8X8XX8H) ; Nitriles ; Pyrimidines ; Pyrazoles
    Language English
    Publishing date 2024-03-13
    Publishing country Germany
    Document type Journal Article ; Multicenter Study ; Clinical Trial
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-024-05704-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.181: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.

    Giallongo, C / Dulcamare, I / Giallongo, S / Duminuco, A / Pieragostino, D / Cufaro, M C / Amorini, A M / Lazzarino, G / Romano, A / Parrinello, N / Di Rosa, M / Broggi, G / Caltabiano, R / Caraglia, M / Scrima, M / Pasquale, L S / Tathode, M S / Li Volti, G / Motterlini, R /
    Di Raimondo, F / Tibullo, D / Palumbo, G A

    Cell death & disease

    2023  Volume 14, Issue 10, Page(s) 686

    Abstract: Ineffective hematopoiesis is a hallmark of myelodysplastic syndromes (MDS). Hematopoietic alterations in MDS patients strictly correlate with microenvironment dysfunctions, eventually affecting also the mesenchymal stromal cell (MSC) compartment. Stromal ...

    Abstract Ineffective hematopoiesis is a hallmark of myelodysplastic syndromes (MDS). Hematopoietic alterations in MDS patients strictly correlate with microenvironment dysfunctions, eventually affecting also the mesenchymal stromal cell (MSC) compartment. Stromal cells are indeed epigenetically reprogrammed to cooperate with leukemic cells and propagate the disease as "tumor unit"; therefore, changes in MSC epigenetic profile might contribute to the hematopoietic perturbations typical of MDS. Here, we unveil that the histone variant macroH2A1 (mH2A1) regulates the crosstalk between epigenetics and inflammation in MDS-MSCs, potentially affecting their hematopoietic support ability. We show that the mH2A1 splicing isoform mH2A1.1 accumulates in MDS-MSCs, correlating with the expression of the Toll-like receptor 4 (TLR4), an important pro-tumor activator of MSC phenotype associated to a pro-inflammatory behavior. MH2A1.1-TLR4 axis was further investigated in HS-5 stromal cells after ectopic mH2A1.1 overexpression (mH2A1.1-OE). Proteomic data confirmed the activation of a pro-inflammatory signature associated to TLR4 and nuclear factor kappa B (NFkB) activation. Moreover, mH2A1.1-OE proteomic profile identified several upregulated proteins associated to DNA and histones hypermethylation, including S-adenosylhomocysteine hydrolase, a strong inhibitor of DNA methyltransferase and of the methyl donor S-adenosyl-methionine (SAM). HPLC analysis confirmed higher SAM/SAH ratio along with a metabolic reprogramming. Interestingly, an increased LDHA nuclear localization was detected both in mH2A1.1-OE cells and MDS-MSCs, probably depending on MSC inflammatory phenotype. Finally, coculturing healthy mH2A1.1-OE MSCs with CD34
    MeSH term(s) Humans ; DNA/metabolism ; Epigenesis, Genetic ; Histones/metabolism ; Inflammation/pathology ; Mesenchymal Stem Cells/metabolism ; Myelodysplastic Syndromes/pathology ; Neoplasms/pathology ; Proteomics ; Toll-Like Receptor 4/metabolism ; Tumor Microenvironment
    Chemical Substances DNA (9007-49-2) ; Histones ; Toll-Like Receptor 4 ; MACROH2A1 protein, human
    Language English
    Publishing date 2023-10-18
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2541626-1
    ISSN 2041-4889 ; 2041-4889
    ISSN (online) 2041-4889
    ISSN 2041-4889
    DOI 10.1038/s41419-023-06197-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.

    Romano, A / Parrinello, N L / Simeon, V / Puglisi, F / La Cava, P / Bellofiore, C / Giallongo, C / Camiolo, G / D'Auria, F / Grieco, V / Larocca, F / Barbato, A / Cambria, D / La Spina, E / Tibullo, D / Palumbo, G A / Conticello, C / Musto, P / Di Raimondo, F

    Scientific reports

    2020  Volume 10, Issue 1, Page(s) 1983

    Abstract: To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, ...

    Abstract To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, we identified a total of 551 upregulated and 343 downregulated genes in MM-HDN, involved in chemokine signaling pathway and FC-gamma receptor mediated phagocytosis conveying in the activation of STAT proteins. In a series of 60 newly diagnosed MM and 30 MGUS patients, by flow-cytometry we found that HDN from MM, and to a lesser extend MGUS, had an up-regulation of the inducible FcγRI (also known as CD64) and a down-regulation of the constitutive FcγRIIIa (also known as CD16) together with a reduced phagocytic activity and oxidative burst, associated to increased immune-suppression that could be reverted by arginase inhibitors in co-culture with lymphocytes. In 43 consecutive newly-diagnosed MM patients, who received first-line treatment based on bortezomib, thalidomide and dexamethasone, high CD64 could identify at diagnosis patients with inferior median overall survival (39.5 versus 86.7 months, p = 0.04). Thus, HDNs are significantly different among healthy, MGUS and MM subjects. In both MGUS and MM neutrophils may play a role in supporting both the increased susceptibility to infection and the immunological dysfunction that leads to tumor progression.
    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Case-Control Studies ; Disease Progression ; Disease Susceptibility/immunology ; Female ; Follow-Up Studies ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Monoclonal Gammopathy of Undetermined Significance/drug therapy ; Monoclonal Gammopathy of Undetermined Significance/genetics ; Monoclonal Gammopathy of Undetermined Significance/immunology ; Monoclonal Gammopathy of Undetermined Significance/mortality ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Neutrophils/immunology ; Neutrophils/metabolism ; Phagocytosis/genetics ; Phagocytosis/immunology ; STAT3 Transcription Factor/metabolism ; Signal Transduction/genetics ; Signal Transduction/immunology ; Tumor Escape/genetics
    Chemical Substances STAT3 Transcription Factor ; STAT3 protein, human
    Language English
    Publishing date 2020-02-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-020-58859-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

    Salpini, R / Surdo, M / Cortese, M F / Palumbo, G A / Carioti, L / Cappiello, G / Spanò, A / Trimoulet, P / Fleury, H / Vecchiet, J / Pasquazzi, C / Mirabelli, C / Scutari, R / Sacco, A / Alkhatib, M / Missale, G / Francioso, S / Sarmati, L / Andreoni, M /
    Angelico, M / Ceccherini-Silberstein, F / Levrero, M / Perno, C F / Belloni, L / Svicher, V

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2018  Volume 25, Issue 7, Page(s) 906.e1–906.e7

    Abstract: Objective: We aimed to investigate HBx genetic elements correlated with hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) and their impact on (a) HBV replicative efficiency, (b) HBx binding to circular covalently closed DNA (cccDNA), (c) ... ...

    Abstract Objective: We aimed to investigate HBx genetic elements correlated with hepatitis B virus (HBV) -related hepatocellular carcinoma (HCC) and their impact on (a) HBV replicative efficiency, (b) HBx binding to circular covalently closed DNA (cccDNA), (c) apoptosis and cell-cycle progression, and (d) HBx structural stability.
    Methods: This study included 123 individuals chronically infected with HBV: 27 with HCC (77.9% (21/27) genotype D; 22.1% (6/27) genotype A) and 96 without HCC (75% (72/96) genotype D; 25.0% (24/96) genotype A). HepG2 cells were transfected by wild-type or mutated linear HBV genome to assess pre-genomic RNA (pgRNA) and core-associated HBV-DNA levels, HBx-binding onto cccDNA by chromatin immunoprecipitation-based quantitative assay, and rate of apoptosis and cell-cycle progression by cytofluorimetry.
    Results: F30V was the only HBx mutation correlated with HCC (18.5% (5/27) in HCC patients versus 1.0% (1/96) in non-HCC patients, p 0.002); a result confirmed by multivariate analysis. In vitro, F30V determined a 40% and 60% reduction in pgRNA and core-associated HBV-DNA compared with wild-type (p <0.05), in parallel with a significant decrease of HBx binding to cccDNA and decreased HBx stability. F30V also decreased the percentage of apoptotic cells compared with wild-type (14.8 ± 6.8% versus 19.1 ± 10.1%, p <0.01, without affecting cell-cycle progression) and increased the probability of HBx-Ser-31 being phosphorylated by PI3K-Akt kinase (known to promote anti-apoptotic activity).
    Conclusions: F30V was closely correlated with HBV-induced HCC in vivo, reduced HBV replicative efficiency by affecting HBx-binding to cccDNA and increased anti-apoptotic HBx activity in vitro. This suggests that F30V (although hampering HBV's replicative capacity) may promote hepatocyte survival, so potentially allowing persistent production of viral progeny and initiating HBV-driven hepatocarcinogenesis. Investigation of viral genetic markers associated with HCC is crucial to identify those patients at higher risk of HCC, who hence deserve intensive liver monitoring and/or early anti-HBV therapy.
    MeSH term(s) Adult ; Aged ; Apoptosis ; Carcinoma, Hepatocellular/virology ; DNA, Viral/genetics ; Female ; Genotype ; Hep G2 Cells ; Hepatitis B virus/genetics ; Hepatitis B virus/physiology ; Hepatitis B, Chronic/virology ; Humans ; Liver/pathology ; Liver Neoplasms/virology ; Male ; Middle Aged ; Mutation ; Structural Homology, Protein ; Trans-Activators/chemistry ; Trans-Activators/genetics ; Virus Replication
    Chemical Substances DNA, Viral ; Trans-Activators ; hepatitis B virus X protein
    Language English
    Publishing date 2018-11-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2018.11.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 284: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Angiogenesis in chronic myeloproliferative diseases.

    Di Raimondo, F / Palumbo, G A / Molica, S / Giustolisi, R

    Acta haematologica

    2001  Volume 106, Issue 4, Page(s) 177–183

    Abstract: Increased angiogenic activity has been demonstrated in myelofibrosis with myeloid metaplasia (MMM), chronic myeloid leukemia (CML), and essential thrombocythemia (ET) by both bone marrow microvessel density evaluation and measurement of circulating ... ...

    Abstract Increased angiogenic activity has been demonstrated in myelofibrosis with myeloid metaplasia (MMM), chronic myeloid leukemia (CML), and essential thrombocythemia (ET) by both bone marrow microvessel density evaluation and measurement of circulating angiogenic factors. MMM is probably the disease with the more pronounced angiogenesis among myeloproliferative disorders but the significance of this finding remains speculative since the angiogenic activity is not correlated with any of the clinical and laboratory features of the disease. Circulating serum levels of angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) were found increased in MMM, CML and ET but the frequent thrombocytosis that accompanies these diseases could limit the interpretation of these data since platelets and megakaryocytes may be considered a major source at least for VEGF. However, CML patients treated with interferon were found to have lower VEGF and HGF levels than untreated or hydroxyurea-treated patients, thus suggesting a possible antiangiogenic mechanism of this drug. In addition, preliminary experiences with the antiangiogenic drug thalidomide have shown therapeutic activity in some myeloproliferative disorders.
    MeSH term(s) Bone Marrow/blood supply ; Bone Marrow/pathology ; Chronic Disease ; Growth Substances/metabolism ; Growth Substances/physiology ; Humans ; Myeloproliferative Disorders/metabolism ; Myeloproliferative Disorders/pathology ; Neovascularization, Pathologic ; Primary Myelofibrosis/metabolism ; Primary Myelofibrosis/pathology
    Chemical Substances Growth Substances
    Language English
    Publishing date 2001
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Terapia del mieloma multiplo.

    Di Raimondo, F / Pennisi, A / Bari, A / Fiumara, P / Palumbo, G A

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

    2005  Volume 22 Suppl 33, Page(s) S46–52

    Abstract: Multiple myeloma (MM) remains an incurable malignancy, the median overal survival of patients receiving conventional chemotherapy being only 36-60 months. MGUS can evolve to MM in a percentage of 0.6-3% per year. The therapeutic management of multiple ... ...

    Title translation Management of multiple myeloma.
    Abstract Multiple myeloma (MM) remains an incurable malignancy, the median overal survival of patients receiving conventional chemotherapy being only 36-60 months. MGUS can evolve to MM in a percentage of 0.6-3% per year. The therapeutic management of multiple myeloma (MM) for the last several decades has mainly involved regimens based on use of glucocorticoids and cytotoxic chemotherapeutics. Melphaln and Prednisone (MP) are recognized as the classic treatment of MM. In patients candidate to bone marrow transplantation, VAD (Vincrisrine, Adriamicin, Dexamethasone) regimen is more indicated because it does not cause stem cell injury. High dose chemotherapy and and Autologous stem cells transplantation represent the best treatment for patients with MM who are younger than 65 years and free of severe comorbidities. Thalidomide alone or in combination with steroids has significant activity in multiple myeloma (MM). After the role of thalidomide in the management of patients with advanced or refractory MM had been established, many studies are evaluating the efficacy and toxicity of thalidomide as first-line therapy for patients with newly diagnosed disease. Recent studies have enhanced our understanding of disease pathogenesis and also provided the framework for a new treatment paradigm targeting the MM cell in its bone marrow microenvironment to overcome drug resistance and improve patient outcome. Clinical trials are confirming the remarkable activity and improved tolerability of some of the new agents identified through this paradigm.
    MeSH term(s) Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/therapy
    Language Italian
    Publishing date 2005-11
    Publishing country Italy
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 1237110-5
    ISSN 0393-5590
    ISSN 0393-5590
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4313: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Angiogenesis in acute myeloid leukemia.

    Di Raimondo, F / Palumbo, G A / Azzaro, M P / Giustolisi, R

    Blood

    2000  Volume 96, Issue 10, Page(s) 3656–3657

    MeSH term(s) Acute Disease ; Biomarkers/blood ; Erythropoietin/blood ; Humans ; Hypoxia/blood ; Leukemia, Myeloid/blood ; Leukemia, Myeloid/physiopathology ; Neovascularization, Pathologic/diagnosis
    Chemical Substances Biomarkers ; Erythropoietin (11096-26-7)
    Language English
    Publishing date 2000-11-15
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.

    Romano, A / Chiarenza, A / Consoli, U / Conticello, C / Forte, S / Uccello, G / Vetro, C / Cavalli, M / Coppolino, F / Palumbo, G A / Di Raimondo, F

    Annals of oncology : official journal of the European Society for Medical Oncology

    2012  Volume 24, Issue 4, Page(s) 1038–1044

    Abstract: Background: A combination of bortezomib (1.3 mg/m(2)), melphalan (5 mg/m(2)), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated.: Patients and methods: Fifty ... ...

    Abstract Background: A combination of bortezomib (1.3 mg/m(2)), melphalan (5 mg/m(2)), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated.
    Patients and methods: Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, 'base' schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, 'weekly' schedule).
    Results: Side-effects were predictable and manageable, with prominent haematological toxicity, and a better toxic profile in 'weekly' schedule (36% versus 66% in 'base' schedule). The overall response rate was 62%. After median follow-up of 24.5 months (range 2.7-50 months), the median progression-free survival (PFS) was 21.6 with no difference between the two schedules and the median overall survival (OS) was 33.8 months. Independently from the adopted schedule, we found that also in a cohort of relapsed/refractory patients achieving at least partial remission improved PFS (35.2 versus 9 months) and OS (unreached median versus 18 months).
    Conclusion: Taken together, our observations suggest that BMD is an effective regimen in advanced myeloma patients with acceptable toxicity.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boronic Acids/administration & dosage ; Boronic Acids/adverse effects ; Bortezomib ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Drug Administration Schedule ; Drug-Related Side Effects and Adverse Reactions/chemically induced ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Follow-Up Studies ; Humans ; Injections, Intravenous ; Male ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Recurrence ; Retrospective Studies ; Treatment Outcome
    Chemical Substances Boronic Acids ; Pyrazines ; Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2012-11-07
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mds531
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

    Milone, G / Poidomani, M / Leotta, S / Avola, G / Camuglia, M G / Privitera, A / Consoli, C / Mercurio, S / Romeo, M A / Di Marco, A / Di Mercurio, S / Spadaro, A / Palumbo, G A / Tedeschi, P

    Bone marrow transplantation

    2012  Volume 47, Issue 1, Page(s) 24–32

    Abstract: Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: ... ...

    Abstract Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group B, those having a CD34+ cell peak between 70 and 183 × 10(9)/L (n=24); group C, those having a CD34+ cell peak >183 × 10(9)/L (n=24). Irrespective of post-remission treatment received, group A had a disease free survival (DFS) of 73%, group B a DFS of 51% and group C of 30% (P=0.0003). In intermediate cytogenetic risk patients, those treated by autologous transplantation had a DFS of 68, 33 and 14% in the groups A, B and C, respectively, (P=0.01) whereas after allogeneic transplantation DFS was 87% in group A+B vs 50% in group C (P=0.009). The peak of CD34+ cells in PB, was an independent predictor for DFS in multivariate analysis.
    MeSH term(s) Adult ; Aged ; Antigens, CD34/blood ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Mobilization/adverse effects ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Leukemia, Myeloid, Acute/blood ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Peripheral Blood Stem Cell Transplantation ; Risk Factors ; Survival Rate ; Transplantation, Autologous ; Transplantation, Homologous
    Chemical Substances Antigens, CD34
    Language English
    Publishing date 2012-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/bmt.2011.33
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

    Giallongo, C / Tibullo, D / La Cava, P / Branca, A / Parrinello, N / Spina, P / Stagno, F / Conticello, C / Chiarenza, A / Vigneri, P / Palumbo, G A / Di Raimondo, F

    Acta haematologica

    2011  Volume 126, Issue 4, Page(s) 205–210

    Abstract: BRIT1 (BRCT-repeat inhibitor of hTERT expression), also known as microcephalin (MCPH1), is a crucial gene in the complex cellular machine that is devoted to DNA repair and acts as a regulator of both the intra-S and G2/M checkpoints. The most important ... ...

    Abstract BRIT1 (BRCT-repeat inhibitor of hTERT expression), also known as microcephalin (MCPH1), is a crucial gene in the complex cellular machine that is devoted to DNA repair and acts as a regulator of both the intra-S and G2/M checkpoints. The most important role of BRIT1/MCPH1 in the regulation of cell cycle progression appears to be the G2/M checkpoint. The K562 and peripheral blood cells of chronic myeloid leukemia (CML) patients at diagnosis were found to downregulate BRIT1/MCPH1. However, we could not find any correlation between bcr/abl activity and the BRIT1/MCPH1 level. In order to study the genomic instability of CML cells, we evaluated the ability of these cells to arrest mitotic division after exposure to hydroxyurea, a known genotoxic agent. We showed that CML cells continue to proliferate without the activation of the G2/M cell cycle checkpoint arrest or of the apoptotic mechanism. This behavior may predispose the cells to accumulate genomic defects. In conclusion, we found that CML cells have a low BRIT1/MCPH1 level and show a defective G2/M arrest, confirming that these cells have a constitutive genomic instability.
    MeSH term(s) Actins/antagonists & inhibitors ; Adult ; Aged ; Cell Proliferation/drug effects ; Cells, Cultured ; Cytochalasin B/toxicity ; Cytokinesis/drug effects ; Female ; G2 Phase Cell Cycle Checkpoints/drug effects ; Gene Expression Regulation, Neoplastic ; Genomic Instability ; Humans ; Hydroxyurea/antagonists & inhibitors ; Hydroxyurea/toxicity ; K562 Cells ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism ; Leukocytes/drug effects ; Leukocytes/metabolism ; Male ; Middle Aged ; Mutagens/toxicity ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Nerve Tissue Proteins/genetics ; Nerve Tissue Proteins/metabolism ; RNA, Messenger/metabolism
    Chemical Substances Actins ; MCPH1 protein, human ; Mutagens ; Neoplasm Proteins ; Nerve Tissue Proteins ; RNA, Messenger ; Cytochalasin B (3CHI920QS7) ; Hydroxyurea (X6Q56QN5QC)
    Language English
    Publishing date 2011
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000329911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.145: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top